• Home
• Patient Assistance
  • Types of Assistance
• Benefits Investigation
• Appeals Assistance
  • Coverage Appeals by Physicians and Patients
  • Prior Authorization Appeals
  • Claim Appeals
  • Medicare Part B Appeals Process
  • FAQs: Medicare Part B Appeals
  • Medicare Part D Appeals Process
  • FAQs: Medicare Part D Appeals
• Products
  • ERBITUX (cetuximab)
    • Prior Authorization Process
    • Coding and Billing Units
    • Diagnosis Coding
    • Documentation for Irinotecan Failure in Colorectal Cancer
    • EGFR Testing in Colorectal Cancer
    • K-ras Testing
    • Medicare Part B Reimbursement
    • Billing for Ancillary Services
    • ERBITUX Patient Assistance
  • IXEMPRA (ixabepilone)
    • Prior Authorization Process
    • Coding and Billing Units
    • Diagnosis Coding
    • Medicare Part B Reimbursement
    • IXEMPRA Patient Assistance
  • SPRYCEL (dasatinib)
    • Prior Authorization Process
    • Medicare Part D Reimbursement
    • SPRYCEL Patient Assistance Program
      • Ship-to-Patient Option
  • YERVOY (ipilimumab)
    • YERVOY Patient Assistance Program
    • Benefits Investigation
    • Appeals Assistance
    • Prior Authorization Process
    • Coding and Billing Units
    • Diagnosis Coding
    • Reimbursement
    • Billing for Ancillary Services
• View Another Product
• Forms and Resources
  • Insurance Overview
  • Forms and Documents
  • Medicare Administrative Contractors (Carriers) by State
  • Glossary

Erbitux^® is a registered trademark of ImClone LLC.

Ixempra and Sprycel are registered trademarks of Bristol-Myers Squibb.

Destination Access is a trademark of Bristol-Myers Squibb.